OCT 01, 2018 4:09 PM PDT

Transplanting Fecal Matter

WRITTEN BY: Nicholas Breehl

The human body has many hidden surprises. One of which is the power fecal matter in the form of a donor gut microbiome. Many patients that have undergone antibiotic therapy to achieve remission from a particular infection can have severe side effects. Opportunistic infections, such as those caused by a particularly nasty bacterium called, Clostridium difficile, can take over a patients gut. When this occurs, more antibiotic therapy can be a potential solution, but, can a donor, fecal microbiome transplant, offer better outcomes for these patients?

A study published in the New England Journal of Medicine provides insight into the effectiveness of a fecal microbiome transplant when compared to antibiotic therapy.

But first, what is it we are talking about here? Poop. Yes, this may seem like a terrible way to overcome a medical situation; however, the science behind the therapy checks out and can even provide a quick recovery.

A fecal transplant is a form of bacteriotherapy where a transfer of stool from a healthy individual is provided to an ill individual. The transfer can be conducted directly via the colon or large intestine making use of colonoscopy, tube insertion into the stomach, or in some cases via pill-form.

In healthy individuals, our gut microbiome is a population of commensal bacteria that aids in our overall digestion. Some of the bacteria are good, and some are considered dangerous. The good bacteria out-compete the bad to a level that the bad does not cause any issue. But when an individual takes antibiotics, the harmful bacteria can sometimes gain advantage and overtake the gut. Fecal microbiome transplants are one of the ways to reconstitute homeostasis.

The observations from the clinical trial in Norway compare 20 adult C. difficile infected patients. One group of 11 patients underwent antibiotic treatments with metronidazole while another group of 9 patients received fecal microbiome transplants.

If the outcome of the method of treatment revealed a clinical cure with no evidence of C. difficile infection or reoccurrence, it was deemed a primary success. If the treatment resulted in the need for further treatment before clearance of C. difficile, it was considered to be to be a secondary success.

Of the 11 patients that received antibiotic treatment, 5 had a full recovery while the remaining six did not experience primary or secondary recovery. Of the nine patients that received a fecal transplant, five experienced full primary recovery, 2 experienced secondary recovery.

These results suggest that a fecal microbiome transplant may be an alternative to antibiotic therapy in C. difficile infection. The team has since moved this therapy to phase three clinical trials to test for efficacy, effectiveness, and safety.

More research is still required to determine the parameters for what makes an ideal donor, however, for now, fecal microbiome transplants are a promising alternative to combat bacterial infections like those caused by c. difficile.

Sources: QDT, Scientific American, MayoClinic, NEJM

About the Author
You May Also Like
MAR 23, 2020
Drug Discovery & Development
MAR 23, 2020
Top 5 Candidates for Coronavirus Vaccine Around the World
It’s easy to complain about the role of big pharma in medicine-making and the hassle of dealing with protective pa ...
APR 01, 2020
Immunology
APR 01, 2020
New Airway-Hugging Immune Cells Discovered in the Lung
  Scientists have discovered a previously unknown subset of immune cells residing in the lung that specifically com ...
APR 07, 2020
Immunology
APR 07, 2020
Too Much Salt Is Bad for the Immune System
Excessive salt intake is associated with health consequences for more than just cardiovascular status; the immune system ...
APR 13, 2020
Cannabis Sciences
APR 13, 2020
Smoking Cannabis Increases COVID-19 Risk
Health experts from the National Institute on Drug Abuse and the American Lung Association have said that smoking cannab ...
APR 20, 2020
Drug Discovery & Development
APR 20, 2020
First Successful Vaccine for Middle-East Respiratory Syndrome
Researchers have successfully completed the first-in-human clinical trial for a vaccine against MERS (Middle East Respir ...
MAY 17, 2020
Genetics & Genomics
MAY 17, 2020
How Non-Coding Genomic Regions Influence Autoimmune Disease
Scientists have gained new insight into autoimmune and allergic disorders.
Loading Comments...